BGB-11417

Phase 2Small molecule

BeiGene

BGB-11417 is one of 164 small molecule programs targeting Mature B-cell Malignancies. It is currently in Phase 2.

Indications

Total Trials

Active Trials

163

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mature B-Cell MalignanciesActive, not recruiting

Acute Myeloid LeukemiaRecruiting

Chronic Lymphocytic Leukemia (CLL)Not yet recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

Mantle Cell LymphomaActive, not recruiting

TEDRecruiting

Mature B-Cell MalignanciesPhase 1

Active, not recruiting

Acute Myeloid LeukemiaPreclinical

Recruiting

Chronic Lymphocytic Leukemia (CLL)Phase 2

Not yet recruiting

Chronic Lymphocytic LeukemiaPhase 2

Active, not recruiting

Mantle Cell LymphomaPhase 2

Active, not recruiting

TEDPhase 2

Recruiting

Competition

Competitive Landscape

255 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Phase 3

34 2

Xospata

Astellas

Phase 3

24 3

Fludara

Sanofi

Phase 3

17 4

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

42 5

Vepesid

AAvyxa

Phase 3

52 6

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 7

Vanflyta

Daiichi Sankyo

Phase 3

14 8

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

30 9

Busulfex

Trexall

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Active, not recruiting

Mantle Cell Lymphoma

NCT05471843

Q3 2027

Phase 2Active, not recruiting

Chronic Lymphocytic Leukemia

NCT05479994

Q3 2028

PreclinicalRecruiting

Acute Myeloid Leukemia

NCT04771130

Q3 2029

Phase 2Recruiting

TED

NCT06463691

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukemia1 trial

Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active, not recruiting· BeiGene logo

BeiGene·Phase 2·NCT05479994·100 enrolled

Mantle Cell Lymphoma1 trial

Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Active, not recruiting· BeiGene logo

BeiGene·Phase 1/2·NCT05471843·125 enrolled

TED1 trial

Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06463691·30 enrolled

Acute Myeloid Leukemia1 trial

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies

Recruiting· BeiGene logo

BeiGene·Preclinical·NCT04771130·260 enrolled

Chronic Lymphocytic Leukemia (CLL)1 trial

A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07508995·40 enrolled

1 more indication

Mature B-cell Malignancies1 trial

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Mature B-cell Malignancies

Active, not recruiting· BeiGene logo

BeiGene·Phase 1·NCT04883957·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for BGB-11417. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BGB-11417 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BGB-11417. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BeiGene company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BeiGene

BGB-11417

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q3 2028

Q3 2029

Trials by Indication[1]

Chronic Lymphocytic Leukemia1 trial

Mantle Cell Lymphoma1 trial

TED1 trial

Acute Myeloid Leukemia1 trial

Chronic Lymphocytic Leukemia (CLL)1 trial

Mature B-cell Malignancies1 trial

References

Drug Info

Quick Facts

Related News